{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Group+1", "query": { "intervention": "Dose Group 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5781, "total_pages": 579, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Group+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T21:46:02.628Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02442648", "title": "B-Cell Targeted Carfilzomib Desensitization", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Transplants and Implants" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "E. Steve Woodle", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2014-12", "completion_date": "2021-09", "has_results": false, "last_update_posted_date": "2020-06-30", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 2, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02442648" }, { "nct_id": "NCT05674643", "title": "Gastric Assessment of Pediatric Patients Undergoing Surgery", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fasting", "Delayed Gastric Emptying", "Aspiration Pneumonia", "Respiratory Aspiration of Gastric Content" ], "interventions": [ { "name": "Gastric Ultrasound Baseline Scans", "type": "DIAGNOSTIC_TEST" }, { "name": "Acetaminophen Absorption Test (AAT)", "type": "DIAGNOSTIC_TEST" }, { "name": "Gastric Ultrasound Serial Scans", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 60, "start_date": "2023-02-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05674643" }, { "nct_id": "NCT02616250", "title": "MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rosacea" ], "interventions": [ { "name": "Brimonidine 0.33% gel (Br)", "type": "DRUG" }, { "name": "CD07805/47 (Br) placebo gel", "type": "OTHER" }, { "name": "Ivermectin 1% cream (IVM)", "type": "DRUG" }, { "name": "CD5024 (IVM) placebo cream", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2015-12", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 7, "location_summary": "Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616250" }, { "nct_id": "NCT00569010", "title": "Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ara-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2005-12", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569010" }, { "nct_id": "NCT06249555", "title": "VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab (VDZ)", "type": "DRUG" }, { "name": "Ustekinumab (UST)", "type": "DRUG" }, { "name": "Risankizumab (RISA)", "type": "DRUG" }, { "name": "Guselkumab (GUS)", "type": "DRUG" }, { "name": "Mirikizumab (MIR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alimentiv Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-03-20", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 11, "location_summary": "Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more", "locations": [ { "city": "Sun City", "state": "Arizona" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06249555" }, { "nct_id": "NCT07226778", "title": "Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overweight", "Obesity" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 348, "start_date": "2025-10-10", "completion_date": "2026-05-28", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 4, "location_summary": "Anaheim, California • Daytona Beach, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226778" }, { "nct_id": "NCT00344968", "title": "Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Fluocinolone Acetonide", "type": "DRUG" }, { "name": "Standard of care laser photocoagulation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Alimera Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 956, "start_date": "2007-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00344968" }, { "nct_id": "NCT00764790", "title": "Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Fluarix", "type": "BIOLOGICAL" }, { "name": "Fluzone", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "35 Months", "sex": "ALL", "summary": "6 Months to 35 Months" }, "enrollment_count": 3317, "start_date": "2008-10-01", "completion_date": "2009-06-01", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Conway", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00764790" }, { "nct_id": "NCT04207359", "title": "Effects of Creatine Supplementation in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Chemotherapy Effect", "Muscle Weakness", "Muscle Loss", "Exercise" ], "interventions": [ { "name": "Creatine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 20, "start_date": "2020-09-30", "completion_date": "2023-03-07", "has_results": false, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04207359" }, { "nct_id": "NCT00441727", "title": "Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Ulcer", "Duodenal Ulcer" ], "interventions": [ { "name": "Esomeprazole 40 mg", "type": "DRUG" }, { "name": "Esomeprazole 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2426, "start_date": "2007-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-07-16", "last_synced_at": "2026-09-08T21:46:02.628Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00441727" } ] }